Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Capital Expenditures (2016 - 2024)

Historic Capital Expenditures for Arcadia Biosciences (RKDA) over the last 11 years, with Q2 2024 value amounting to $3000.0.

  • Arcadia Biosciences' Capital Expenditures fell 4000.0% to $3000.0 in Q2 2024 from the same period last year, while for Mar 2025 it was $3000.0, marking a year-over-year decrease of 8333.33%. This contributed to the annual value of $16000.0 for FY2024, which is 22000.0% up from last year.
  • According to the latest figures from Q2 2024, Arcadia Biosciences' Capital Expenditures is $3000.0, which was down 4000.0% from $13000.0 recorded in Q1 2024.
  • Arcadia Biosciences' Capital Expenditures' 5-year high stood at $971000.0 during Q2 2020, with a 5-year trough of $3000.0 in Q2 2024.
  • Its 5-year average for Capital Expenditures is $245357.1, with a median of $147000.0 in 2021.
  • In the last 5 years, Arcadia Biosciences' Capital Expenditures skyrocketed by 78409.09% in 2020 and then plummeted by 9736.84% in 2022.
  • Over the past 5 years, Arcadia Biosciences' Capital Expenditures (Quarter) stood at $297000.0 in 2020, then plummeted by 70.37% to $88000.0 in 2021, then tumbled by 70.45% to $26000.0 in 2022, then crashed by 80.77% to $5000.0 in 2023, then plummeted by 40.0% to $3000.0 in 2024.
  • Its Capital Expenditures was $3000.0 in Q2 2024, compared to $13000.0 in Q1 2024 and $5000.0 in Q2 2023.